Time to blood pressure control and predictors among patients receiving integrated treatment for hypertension and HIV based on an adapted WHO HEARTS implementation strategy at a large urban HIV clinic in Uganda

Willington Amutuhaire,Fred Collins Semitala,Isaac Derick Kimera,Christabellah Namugenyi,Frank Mulindwa,Rebecca Ssenyonjo,Rodgers Katwesigye,Frank Mugabe,Gerald Mutungi,Isaac Ssinabulya,Jeremy I. Schwartz,Anne R. Katahoire,Lewis S. Musoke,George A. Yendewa,Chris T. Longenecker,Martin Muddu
DOI: https://doi.org/10.1038/s41371-024-00897-3
2024-02-02
Journal of Human Hypertension
Abstract:In this cohort study, we determined time to blood pressure (BP) control and its predictors among hypertensive PLHIV enrolled in integrated hypertension-HIV care based on the World Health Organization (WHO) HEARTS strategy at Mulago Immunosuppression Clinic in Uganda. From August 2019 to March 2020, we enrolled hypertensive PLHIV aged 18 years and initiated Amlodipine 5 mg mono-therapy for BP (140–159)/(90–99) mmHg or Amlodipine 5 mg/Valsartan 80 mg duo-therapy for BP ≥ 160/90 mmHg. Patients were followed with a treatment escalation plan until BP control, defined as BP 10 years was associated with a shorter time to BP control (aHR 1.456, 95% CI 1.126–1.883). The WHO HEARTS strategy was effective at achieving timely BP control among PLHIV. Additionally, monotherapy anti-hypertensive treatment for stage I hypertension is a viable option to achieve BP control and limit pill burden in resource limited HIV care settings.
peripheral vascular disease
What problem does this paper attempt to address?